Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 85-87

  Di Poi, Emma ^a   Perin, Antonella ^a   Morassi, Maria Pia ^b   Del Frate, Marino ^c   Ferraccioli, Gian Franco ^d   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b Division of Internal Medicine   (Italy)

^c Rheumatology Unit   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Efficacy; Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

CHLOROQUINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE;

EID: 33947588655     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. CHOY EH, PANAY GS: Cytokine pathway and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
2. MAINI RN, ST CLAIR EW, BREEDWELD F et al.: Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-9.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
4. BROCQ O, PLUBEL Y, BREUIL V et al.: Etanercept-infliximab switch in rheumatoid arthritis in 14 out of 131 patients treated with anti-TNFalpha. Presse Med 2002 Nov 23; 31 (39 Pt 1): 1836-9.
5. ARNETT FC, EDWARTHY SM, BLACK DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998; 31: 315-24.
6. van GESTEL AM, ANDERSON JJ, von RIEL PL et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999 Mar; 26: 705-11.
7. GOMEZ-PUERTA JA, SANMARTÌ R, RODRÌGUEZ-CROS JR, CANUTE JD: Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004; 63: 896.
8. HANSEN KE, HILDEBRAND JP, GENOVESE MC et al.: The efficacy of switching from Etanercept to Infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1098-102.
9. Van VOLLEN RF: Switching between biological agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S115-21.
10. SCALLON BJ, MOORE MA, TRINH H, KNIGH DM; GHRAYEB J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
11. St CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
12. LEE H, KIMKO HC, ROGGE M, WANG D, NESTOROV I, PECK CC: Population pharmacokinetics and phamacodynamics modelling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003; 73: 348-65.
13. van den BRANDE JM, BRAAT H, van den BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 Jun; 124: 1774-85.
14. SACCA R, CUFF CA, LESSLAURER W, RUDDLE NH: Differential activities of secreted lymphotoxin 3 and membrane lymphotoxin-1b2 in lymphotoxic induced inflammation: critical role of TNF receptor 1 signaling. J Immunol 1998; 160: 485-91.
15. FABRIS M, DI POI E, D'ELIA A, DAMANTE G, SINIGALIA L, FERRACCIOLI GF: Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002; 29: 29-33.
16. COSTANTIN A, DIEUDE P, LAUWERS-CANCES V et al.: Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum 2004; 50: 742-7.